Inactive Instrument

Roche Holding AG Stock Xetra

Equities

RHO

CH0012032113

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 60B 66.01B 61.17B Sales 2025 * 63.79B 70.19B 65.04B Capitalization 184B 202B 187B
Net income 2024 * 13.46B 14.81B 13.72B Net income 2025 * 14.87B 16.36B 15.16B EV / Sales 2024 * 3.3 x
Net Debt 2024 * 14.25B 15.68B 14.53B Net Debt 2025 * 8.18B 9B 8.34B EV / Sales 2025 * 3.01 x
P/E ratio 2024 *
13.3 x
P/E ratio 2025 *
12.1 x
Employees 103,605
Yield 2024 *
4.27%
Yield 2025 *
4.41%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 66 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW